Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia
Objectives Acute T-cell lymphoblastic leukemia (T-ALL) is a severe hematologic malignancy with limited treatment options and poor long-term survival. This study explores the role of IKZF1 in regulating BCL-2 expression in T-ALL.Methods CUT&Tag and CUT&Run assays were employed to assess IKZF1...
Saved in:
Main Authors: | Juan Li, Chunmei Ye, Hui Li, Jun Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Cancer Biology & Therapy |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/15384047.2025.2457777 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies
by: Mariam Markouli, et al.
Published: (2025-01-01) -
The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
by: Xiaoxia Wu, et al.
Published: (2024-09-01) -
Secondary neoplasms in survivors of pediatric acute lymphoblastic leukemia and lymphoblastic lymphoma: a single-center, retrospective study
by: Eri Ushida, et al.
Published: (2025-01-01) -
Acute Neurotoxicity in Children Treated for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: A 10-Year Single-Centre Experience
by: Izabela Kranjčec, et al.
Published: (2024-12-01) -
Incidence of secondary malignancies in Polish children treated for acute lymphoblastic leukemia according to the ALL-IC BFM 2002 protocol
by: Kamila Wypyszczak, et al.
Published: (2024-12-01)